Atrioventricular Synchronous Pacing Using a Leadless Ventricular Pacemaker: Results From the MARVEL 2 Study.


Journal

JACC. Clinical electrophysiology
ISSN: 2405-5018
Titre abrégé: JACC Clin Electrophysiol
Pays: United States
ID NLM: 101656995

Informations de publication

Date de publication:
01 2020
Historique:
received: 24 10 2019
revised: 31 10 2019
accepted: 31 10 2019
pubmed: 12 11 2019
medline: 10 4 2021
entrez: 12 11 2019
Statut: ppublish

Résumé

This study reports on the performance of a leadless ventricular pacemaker with automated, enhanced accelerometer-based algorithms that provide atrioventricular (AV) synchronous pacing. Despite many advantages, leadless pacemakers are currently only capable of single-chamber ventricular pacing. The prospective MARVEL 2 (Micra Atrial tRacking using a Ventricular accELerometer 2) study assessed the performance of an automated, enhanced accelerometer-based algorithm downloaded to the Micra leadless pacemaker for up to 5 h in patients with AV block. The primary efficacy objective was to demonstrate the superiority of the algorithm to provide AV synchronous (VDD) pacing versus VVI-50 pacing in patients with sinus rhythm and complete AV block. The primary safety objective was to demonstrate that the algorithm did not result in pauses or heart rates of >100 beats/min. Overall, 75 patients from 12 centers were enrolled; an accelerometer-based algorithm was downloaded to their leadless pacemakers. Among the 40 patients with sinus rhythm and complete AV block included in the primary efficacy objective analysis, the proportion of patients with ≥70% AV synchrony at rest was significantly greater with VDD pacing than with VVI pacing (95% vs. 0%; p < 0.001). The mean percentage of AV synchrony increased from 26.8% (median: 26.9%) during VVI pacing to 89.2% (median: 94.3%) during VDD pacing. There were no pauses or episodes of oversensing-induced tachycardia reported during VDD pacing in all 75 patients. Accelerometer-based atrial sensing with an automated, enhanced algorithm significantly improved AV synchrony in patients with sinus rhythm and AV block who were implanted with a leadless ventricular pacemaker. (Micra Atrial Tracking Using a Ventricular Accelerometer 2 [MARVEL 2]; NCT03752151).

Sections du résumé

OBJECTIVES
This study reports on the performance of a leadless ventricular pacemaker with automated, enhanced accelerometer-based algorithms that provide atrioventricular (AV) synchronous pacing.
BACKGROUND
Despite many advantages, leadless pacemakers are currently only capable of single-chamber ventricular pacing.
METHODS
The prospective MARVEL 2 (Micra Atrial tRacking using a Ventricular accELerometer 2) study assessed the performance of an automated, enhanced accelerometer-based algorithm downloaded to the Micra leadless pacemaker for up to 5 h in patients with AV block. The primary efficacy objective was to demonstrate the superiority of the algorithm to provide AV synchronous (VDD) pacing versus VVI-50 pacing in patients with sinus rhythm and complete AV block. The primary safety objective was to demonstrate that the algorithm did not result in pauses or heart rates of >100 beats/min.
RESULTS
Overall, 75 patients from 12 centers were enrolled; an accelerometer-based algorithm was downloaded to their leadless pacemakers. Among the 40 patients with sinus rhythm and complete AV block included in the primary efficacy objective analysis, the proportion of patients with ≥70% AV synchrony at rest was significantly greater with VDD pacing than with VVI pacing (95% vs. 0%; p < 0.001). The mean percentage of AV synchrony increased from 26.8% (median: 26.9%) during VVI pacing to 89.2% (median: 94.3%) during VDD pacing. There were no pauses or episodes of oversensing-induced tachycardia reported during VDD pacing in all 75 patients.
CONCLUSIONS
Accelerometer-based atrial sensing with an automated, enhanced algorithm significantly improved AV synchrony in patients with sinus rhythm and AV block who were implanted with a leadless ventricular pacemaker. (Micra Atrial Tracking Using a Ventricular Accelerometer 2 [MARVEL 2]; NCT03752151).

Identifiants

pubmed: 31709982
pii: S2405-500X(19)30843-6
doi: 10.1016/j.jacep.2019.10.017
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT03752151']

Types de publication

Clinical Trial Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

94-106

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Clemens Steinwender (C)

Department of Cardiology, Kepler University Hospital, Linz, Austria; Department of Cardiology, Paracelsus Medical University Salzburg, Salzburg, Austria. Electronic address: clemens.steinwender@kepleruniklinikum.at.

Surinder Kaur Khelae (SK)

Department of Electrophysiology, Institut Jantung Negara, Kuala Lumpur, Malaysia.

Christophe Garweg (C)

Department of Cardiovascular Sciences, Department of Cardiology, University Hospitals Leuven, Leuven, Belgium.

Joseph Yat Sun Chan (JYS)

Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, Hong Kong.

Philippe Ritter (P)

Department of Electrophysiology and Cardiac Stimulation, Hôpital Haut- Lévêque - CHU de Bordeaux, Pessac, France.

Jens Brock Johansen (JB)

Department of Cardiology, Odense University Hospital, Odense, Denmark.

Venkata Sagi (V)

Baptist Heart Specialists, Baptist Medical Center Jacksonville, Florida, USA.

Laurence M Epstein (LM)

Department of Electrophysiology, North Shore University Hospital, Manhasset, New York, USA.

Jonathan P Piccini (JP)

Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA.

Mario Pascual (M)

Miami Cardiac & Vascular Institute, Baptist Hospital, Miami, Florida.

Lluis Mont (L)

Institut Clinic Cardiovascular (ICCV), Hospital Clínic, Universitat de Barcelona, Catalonia, Barcelona, Spain.

Todd Sheldon (T)

Medtronic, Inc., Mounds View, Minnesota, USA.

Vincent Splett (V)

Medtronic, Inc., Mounds View, Minnesota, USA.

Kurt Stromberg (K)

Medtronic, Inc., Mounds View, Minnesota, USA.

Nicole Wood (N)

Medtronic, Inc., Mounds View, Minnesota, USA.

Larry Chinitz (L)

Leon H. Charney Division of Cardiology, NYU Langone Medical Center, New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH